The specific aims of ClinSeq include: 1. Pilot the development of a robust infrastructure for the generation and use of LSMS data from subjects in a clinical research setting. This will involve the coupling of the NISC production-oriented DNA sequencing group with the NIH Clinical Research Center. We will establish technical expertise for generating, handling, and interpreting LSMS clinical research data. 2. Use LSMS data to address biomedical research questions. For example: (l) testing associations of genomic variants with quantitative traits identified in subjects (such as atherosclerosis and lipid levels);(2) using LSMS data to identify subsets of subjects from the prospective cohort, who can then be invited to return to the NIH Clinical Research Center for additional phenotyping and in-depth study: and (3) using this cohort for replication studies of associations of genomic variants and phenotypes. A cohort of 1,000 individuals will be evaluated at the NIH Clinical Research Center for a set of cardiovascular phenotypic features, including, but not limited to, coronary artery calcification, lipid profiles, and blood pressure. Participants will be selected to fall within a spectrum of coronary artery calcification from normal to disease phenotype. Participants will undergo a clinical evaluation, targeted clinical tests, and blood sample collection for genomic analysis and they will provide baseline information about pertinent health behavior and a family history. Exome sequencing of peripheral blood DNA will be performed on all samples and has been completed in >600 subjects to date. Importantly, ClinSeq subjects will be consented for return of results (both research and clinical results) and for re-contact for iterative phenotyping. ClinSeq was designed in a way that will provide the long-term potential for pursuing many different clinical projects. We propose to select subsets of subjects from the ClinSeq dataset, identified by their genomic attributes, explore their phenotypic manifestations, as a new path to understanding genotype-phenotype relationships.

Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2011
Total Cost
$1,229,401
Indirect Cost
Name
National Human Genome Research Institute
Department
Type
DUNS #
City
State
Country
Zip Code
Biesecker, Leslie G; Harrison, Steven M (2018) The ACMG/AMP reputable source criteria for the interpretation of sequence variants. Genet Med :
Sapp, Julie C; Johnston, Jennifer J; Driscoll, Kate et al. (2018) Evaluation of Recipients of Positive and Negative Secondary Findings Evaluations in a Hybrid CLIA-Research Sequencing Pilot. Am J Hum Genet 103:358-366
Hellwig, Lydia D; Biesecker, Barbara B; Lewis, Katie L et al. (2018) Ability of Patients to Distinguish Among Cardiac Genomic Variant Subclassifications. Circ Genom Precis Med 11:e001975
Biesecker, Barbara B; Lewis, Katie L; Biesecker, Leslie G (2018) Web-Based Platform vs Genetic Counselors in Educating Patients About Carrier Results From Exome Sequencing-Reply. JAMA Intern Med 178:999
Miller, Ilana M; Lewis, Katie L; Lawal, Tokunbor A et al. (2018) Health behaviors among unaffected participants following receipt of variants of uncertain significance in cardiomyopathy-associated genes. Genet Med :
Tavtigian, Sean V; Greenblatt, Marc S; Harrison, Steven M et al. (2018) Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med 20:1054-1060
Sanghvi, Rashesh V; Buhay, Christian J; Powell, Bradford C et al. (2018) Characterizing reduced coverage regions through comparison of exome and genome sequencing data across 10 centers. Genet Med 20:855-866
Lewis, Katie L; Umstead, Kendall L; Johnston, Jennifer J et al. (2018) Outcomes of Counseling after Education about Carrier Results: A Randomized Controlled Trial. Am J Hum Genet 102:540-546
Lawal, T A; Lewis, K L; Johnston, J J et al. (2018) Disclosure of cardiac variants of uncertain significance results in an exome cohort. Clin Genet 93:1022-1029
Ng, David; Hong, Celine S; Singh, Larry N et al. (2017) Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening. Genet Med 19:357-361

Showing the most recent 10 out of 68 publications